| Symbol | CRVO |
|---|---|
| Name | CERVOMED INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 300 EAST MAIN STREET,SUITE 201, CHARLOTTESVILLE, Virginia, 22902, United States |
| Telephone | +1 434 220-0718 |
| Fax | — |
| — | |
| Website | https://www.cervomed.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001053691 |
| Description | CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimers disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. Additional info from NASDAQ: |
New Form ARS - CervoMed Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001437749-26-014200 <b>Size:</b> 1 MB
Read more(99% Neutral) CERVOMED INC. (CRVO) Provides Update on treatments for Chicago
Read moreCervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
Read more(70% Positive) CERVOMED INC. (CRVO) Provides Update on treatments for age-related brain disorders
Read moreNew Form SCHEDULE 13G/A - CervoMed Inc. <b>Filed:</b> 2026-04-07 <b>AccNo:</b> 0001535264-26-000017 <b>Size:</b> 9 KB
Read moreCervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
Read more(85% Positive) CERVOMED INC. (CRVO) Provides Update on regimen for planned Phase 3 trial BOSTON
Read moreCervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
Read moreCervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07033481 | Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia | Phase2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Recruiting | 2025-10-02 | 2026-10-01 | ClinicalTrials.gov |
| NCT06987643 | A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recove… | Phase2 | Moderate to Severe Acute Ischaemic Stroke | Recruiting | 2025-06-20 | 2026-06-28 | ClinicalTrials.gov |
| NCT06815965 | A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies | Phase2 | Dementia With Lewy Bodies (DLB) | Completed | 2024-10-16 | 2026-03-25 | ClinicalTrials.gov |
| NCT05869669 | RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy … | Phase2 | Dementia With Lewy Bodies | Completed | 2023-05-01 | 2025-06-16 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Phase PHASE2 | Moderate to Severe Acute Ischaemic Stroke | RECRUITING | NCT06987643 |
| Neflamapimod | Other | Phase PHASE2 | Moderate to Severe Acute Ischaemic Stroke | RECRUITING | NCT06987643 |
| Placebo | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| Neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies | COMPLETED | NCT05869669 |
| neflamapimod | Other | Phase PHASE2 | Dementia With Lewy Bodies (DLB) | COMPLETED | NCT06815965 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Placebo | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | Other | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| neflamapimod | DRUG | Phase PHASE2 | Dementia With Lewy Bodies (DLB) | COMPLETED | NCT06815965 |
| Placebo | DRUG | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |
| Neflamapimod | DRUG | Phase PHASE2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | RECRUITING | NCT07033481 |